Alterations of fecal bacterial communities in patients with lung cancer
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study asked whether the gut bacterial community differs in people with lung cancer, and whether specific bacteria track with inflammation. Researchers sequenced the hypervariable V1-V2 regions of the 16S rRNA gene from fecal samples. They compared lung cancer patients with healthy volunteers. They also measured serum inflammatory biomarkers and tested correlations between specific bacteria and those markers. The design was observational and cross-sectional. It aimed to characterize a gut-lung link that had not been directly described before.
Who was studied?
The cohort was human adults: patients with lung cancer compared against healthy control volunteers. All samples were stool, analyzed by 16S rRNA gene sequencing of the V1-V2 region. The work was conducted in China. The comparison was disease versus healthy, not a treatment trial. The report notes significant interindividual variation between participants. Despite this variation, group-level differences in community membership were still detected.
What were the most important findings?
Unweighted principal coordinate analysis showed a clear separation between the lung cancer and healthy groups. Community membership differed between the two groups. Eight predominant genera differed significantly between groups (p less than 0.05). Some genera were elevated in lung cancer while others were depleted relative to healthy controls. Certain specific bacteria correlated with serum inflammatory biomarkers. The authors state this is the first study to report correlations between specific gut bacteria and inflammatory indicators in lung cancer.
What are the greatest implications of this study?
The results show that gut bacterial composition is altered in lung cancer and links to systemic inflammation. This supports investigating a gut-lung axis in this disease. The study is cross-sectional, so it cannot show whether dysbiosis causes cancer or results from it. Interindividual variation was significant. The authors call for animal model studies to probe the underlying mechanisms of gut bacteria in lung cancer.